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Abstract The global malaria burden has decreased over the last decade and many nations are
attempting elimination. Asymptomatic malaria infections are not normally diagnosed or treated,
posing a major hurdle for elimination efforts. One solution to this problem is mass drug
administration (MDA), with success depending on adequate population participation. Here, we
present a detailed spatial and temporal analysis of malaria episodes and asymptomatic infections in
four villages undergoing MDA in Myanmar. In this study, individuals from neighborhoods with low
MDA adherence had 2.85 times the odds of having a malaria episode post-MDA in comparison to
those from high adherence neighborhoods, regardless of individual participation, suggesting a
herd effect. High mosquito biting rates, living in a house with someone else with malaria, or having
an asymptomatic malaria infection were also predictors of clinical episodes. Spatial clustering of
non-adherence to MDA, even in villages with high overall participation, may frustrate elimination
efforts.
DOI: https://doi.org/10.7554/eLife.41023.001
Introduction
Mass drug administration (MDA) is the provision of medications to entire target populations and the
approach has been used for many infectious diseases, including lymphatic filariasis, soil-transmitted
helminths, onchocerciasis, schistosomiasis, and trachoma (Keenan et al., 2013). MDA has historically
been used for P. falciparum malaria (Poirot et al., 2013) and has recently been trialed in several
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locations in Africa (Gitaka et al., 2017; Mwesigwa et al., 2018; Shekalaghe et al., 2011) and Asia
(Manning et al., 2018; Tripura et al., 2018; Nguyen et al., 2018; Pongvongsa et al., 2018;
Landier et al., 2017a). It is being considered by several nations as a tool (to be used in unison with
other interventions) for elimination (World Health Organization, 2017; Zuber and Takala-Harrison,
2018), and has already been implemented as an operational strategy in at least one modern setting
(Parker et al., 2017; Landier et al., 2018a).
Given that drug pressure (through provision of antimalarial drugs) provides a survival advantage
for resistant parasites, there has been some hesitance in using MDA for malaria. One historical
malaria eradication campaign relied on the inclusion of sub-therapeutic levels of antimalarials distrib-
uted in table salt across large populations (Pinotti et al., 1955). This program likely led to the emer-
gence of parasite resistance in the same regions (Wootton et al., 2002) and this has in part led to
hesitance among some institutions (i.e. the World Health Organization and ministries of health) to
implement MDA for malaria (World Health Organization, 2015a). MDA should ideally be used in
settings with strong public health infrastructure, including easy access to diagnosis and treatment;
an up-to-date and responsive surveillance system; and effective community engagement. Used
appropriately, MDA can quickly reduce or eliminate parasite reservoirs and can act as a catalyst for
subregional elimination of P. falciparum malaria (Landier et al., 2018a).
While antimalarials are usually administered following diagnosis (confirmed or presumed) or used
as a prophylactic, MDA is used because of an intended population- or community-level effect. The
rationale is that the transmission potential or reproductive rate of malaria is so high that a sufficient
amount of the parasite reservoir needs to be removed in order to disrupt transmission. This group-
level effect is also referred to as a ‘herd effect’ (John and Samuel, 2000; Pollard et al., 2015) and
the concept applies to most communicable diseases. If a sufficient amount of the population partici-
pates in MDA, transmission chains cannot be sustained and transmission will cease, ultimately lead-
ing to a reduction in malaria morbidity and mortality (World Health Organization, 2017). There is
likely to be a context-specific critical threshold for MDA coverage, below which the reduction of the
parasite reservoir is not sufficient to halt ongoing transmission. Some literature has suggested that
at least 80% coverage and adherence of MDA in the targeted population is necessary in order for
eLife digest The global burden of malaria has decreased over the last decade. Many countries
now aim to banish malaria. One obstacle to elimination is people who carry malaria parasites
without showing symptoms. These asymptomatic people are unlikely to be diagnosed and treated
and may contribute to further spread of malaria. One way to clear all malaria infections would be to
ask everyone in a community to take antimalarial drugs at the same time, even if they do not feel ill.
This tactic is most likely to work in communities that are already reducing malaria infections by other
means. For example, by treating symptomatic people and using bed nets to prevent bites from
malaria-infected mosquitos.
Several studies have shown that mass drug administration is a promising approach to reduce
malaria infections. But its success depends on enough people participating. If enough community
members take antimalarial drugs, then even those who cannot participate, such as young children or
pregnant women, should be less likely to get malaria. This is called the herd effect.
Now, Parker et al. demonstrate that mass antimalarial drug administration reduces infections with
malaria caused by the parasite Plasmodium falciparum. The analysis looked at malaria infections
among residents of four villages in the Kayin State of Myanmar that used mass antimalarial drug
administration. People who lived in neighborhoods with high participation in mass drug
administration were almost three times less likely to get malaria than people who lived in
communities with low participation. Even people who did not take part benefited.
The analysis suggests that mass antimalaria drug administration benefits individuals and their
communities if enough people take part. To be successful, malaria elimination programs that wish to
use mass drug administration should approach communities in a way that encourages high levels of
participation.
DOI: https://doi.org/10.7554/eLife.41023.002
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the MDA to be successful (World Health Organization, 2015b). If the aim for antimalarial MDA is
to interrupt transmission, the notion of a herd effect providing additional levels of population pro-
tection is plausible but has not been examined empirically (Cotter et al., 2013).
Drawing from detailed micro-epidemiological and spatial data from an MDA trial in Kayin State,
Myanmar (Figure 1), we describe geographic and epidemiological patterns of clinical and subclinical
P. falciparum malaria in villages undergoing MDA. We investigate associations between individual-
and group-level participation in MDA (potential direct and indirect effects, respectively); subclinical
infections; and clinical episodes of P. falciparum post-MDA. Such empirical research is important for
providing an evidence base for further research, intervention, and policy work.
Results
3229 villagers (1689 male) were included in this study. During the study period, 80 study participants
were diagnosed with clinical P. falciparum. 201 participants were found to have P. falciparum by
uPCR. 325 uPCR-positive participants had Plasmodium infections not identifiable at the species level
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Figure 1. Map indicating the locations of the study villages along the Myanmar-Thailand border; and the distribution of houses, mosquito catch sites
and malaria posts within study sites.
DOI: https://doi.org/10.7554/eLife.41023.003
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and thus were not included in these analyses. Total numbers of clinical episodes and uPCR-detected
infections were higher than the total number of infected individuals because some participants had
multiple infections.
After MDA, the vast majority of clinical P. falciparum episodes occurred in only one of the study
villages (TOT). 66 out of the 80 participants who had a clinical P. falciparum episode were from TOT
village (three from HKT, seven from TPN and four from KNH).
Eleven of the 80 participants (14%) who had a clinical P. falciparum episode during the study
period had repeated clinical episodes and 19 of the 80 (24%) participants who had a clinical episode
were found to have a uPCR-detected P. falciparum infection in at least one of the surveys. uPCR-
detected P. falciparum infections were more prevalent in males than females (UOR: 2.03; CI: 1.50–
2.76).
Spatiotemporal patterns in clinical episodes, uPCR-detected infections,
and MDA adherence
uPCR-detected P. falciparum infections were widespread in all villages at baseline (Figure 2). These
infections were significantly reduced following MDA in all villages. The prevalence of uPCR-detected
P. falciparum infections had reduced in two control villages (villages TPN and HKT) prior to MDA.
There were statistically significant clusters of uPCR-detected P. falciparum infections in each vil-
lage at baseline but subsequently no significant clusters were detected (Figure 2). Clusters of clinical
P. falciparum episodes occurred in two villages (KNH and TOT). The cluster in KNH occurred from
M5 through M7 but included only four episodes. There were two separate clusters in village TOT. A
cluster in the western portion of the village began in M12 and lasted until M18 (with a total of 35
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Figure 2. Clinical P.falciparum episodes (yellow square points) and uPCR-detected P. falciparum infections (blue dots) at house level over time (by
survey month; month 0 (M0) through month 24 (M24)) for each of the four study villages. Statistically significant clusters (detected using SaTScan) are
indicated for both clinical episodes (underlying yellow circles) and uPCR-detected infections (underlying blue circles). Grey points indicate house
locations for houses with no infections or episodes in a given time. In the maps clinical episodes are aggregated to align with surveys (i.e. M1, M2 and
M3 aggregated into M3), though they were recorded and analyzed by individual month. The study was conducted from May 2013 through June 2015
(KNH began in June; TPN in May; HKT in July; and TOT in May of 2013).
DOI: https://doi.org/10.7554/eLife.41023.004
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episodes). A single-house cluster occurred in the eastern portion of the village (M15 through M18)
with five episodes among four house members (2 in a 10 yo male, 1 in a 48 yo male, 1 in a 16 yo
male, and 1 in a 48-year-old female).
There were significant clusters of non-participation in the MDAs in three of the study villages
(TPN, HKT and TOT (Appendix 1—figure 2)). The non-participation cluster in TOT made up a large
portion of the western part of the village and included 115 individuals not participating in the MDA
(out of 919 total individuals in TOT). The non-participation clusters in HKT and TPN included 206
and 15 individuals respectively.
Sporadic clinical P. falciparum episodes occurred in village TOT following MDA (MDA was com-
pleted by M3), followed by a small outbreak beginning in M12 (Figures 2 and 3). The first clinical P.
falciparum episodes during this outbreak occurred among villagers who lived in the cluster of non-
MDA participation (Figure 3). By M15 the clinical episodes were occurring through much of the vil-
lage (Figure 3).
Cumulative hazards plots of clinical P. falciparum episodes in village TOT illustrate the temporal
patterns in infections according to neighborhood MDA non-adherence (aggregated into terciles)
and individual participation in MDA (Figure 4). The proportion of individuals who had acquired a
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Figure 3. Spatiotemporal distribution of clinical P.falciparum episodes (yellow square points), uPCR-detected P. falciparum infections (blue dots), and a
cluster of non-participation in MDA (grey circle/ochre border, detected using SatScan) in TOT village. Season is indicated by colored squares in the top
right corner of each map. A measure of the spread of clinical P. falciparum cases is given by the standard distance deviation (‘SDD’), indicated by the
hollow circle with dark grey outline. One standard deviation is shown, indicating that roughly 68% of all cases lie inside of the circle. After MDA (M3),
clinical episodes began occurring in the westernmost portion of the village. By month 15 (M15), clinical episodes were occurring throughout the village.
DOI: https://doi.org/10.7554/eLife.41023.005
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Figure 4. Cumulative hazard of having a clinical P. falciparum episode by MDA adherence. Cumulative hazard for clinical P. falciparum episodes in
village TOT by (A) neighborhood MDA adherence (‘low non-adhere’ is a neighborhood with a low proportion of non-adherents; ‘high non-adhere’ is a
neighborhood with a high proportion of non-adherents), (B) neighborhood adherence (same as in A) and individual adherence (‘individual non-
participation’ indicates individuals who took no MDA while ‘individual participation’ indicates individuals who took at least 1 round of MDA). Figure 4B
Figure 4 continued on next page
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clinical P. falciparum episode began consistently increasing in M12 for those living in either mid or
high MDA non-adherence neighborhoods. P. falciparum episodes among low MDA non-adherence
neighborhoods began increasing approximately 1 month after the increase in high non-adherence
neighborhoods but never reached the level experienced in either mid or high MDA non-adherence
neighborhoods. 4.4% of all individuals in low MDA non-adherence neighborhoods had at least one
clinical P. falciparum episode by the end of the study period, in comparison to 7.6% in mid and 9.6%
in high MDA non-adherence neighborhoods (log-rank test p-value=0.0485; Figure 4A).
The increase in clinical P. falciparum episodes in M12 also coincided with an increase in HBR in vil-
lage TOT (Appendix 1—figure 3).
Longitudinal multivariable analysis of clinical P. falciparum episodes
After MDA, clinical P. falciparum episodes in village TOT were most likely to occur among 5 to 14
year olds (AOR: 3.41; CI: 1.33–8.77, compared to 0 to 4 year olds) and participants who lived in a
house with someone else who had a clinical P. falciparum episode during the same month (AOR:
3.43; CI: 1.52–7.72), after adjusting for other covariates (Table 1). Individuals who lived in a neigh-
borhood with a high proportion of people who did not adhere to MDA had 2.8 times the odds of
having a clinical episode (AOR: 2.85; CI: 1.28–6.37) compared to people who lived in neighborhoods
where most people adhered to MDA (Table 1). The human biting rate was also associated with
increased odds of having a clinical P. falciparum episode, with a 10% increase in odds for every one
unit increase in HBR (AOR: 1.09; CI: 1.05–1.13).
Figure 4 continued
indicates that individuals who participated in MDA and lived in a neighborhood with low adherence had the highest risk of having a clinical episode
post-MDA. Individuals who took no rounds of MDA but lived in a neighborhood with a high proportion of adherents had the lowest risk of acquiring a
clinical episode post-MDA.
DOI: https://doi.org/10.7554/eLife.41023.006
Table 1. Multivariable mixed effects logistic regression for odds of having a clinical P. falciparum
episode (village TOT only).
The model includes a random intercept for individual participants, with repeat observations occurring
within individuals over the study period.
Covariate AOR p-Value
Age 0 to 4 Comparison
Age 5 to 14 3.41 (1.33–8.77) 0.0104
Age 15 plus 2.17 (0.86–5.46) 0.1053
Female Comparison
Male 1.19 (0.66–2.11) 0.5612
Participated in no rounds of MDA Comparison
Participated in MDA (at least one round) 1.43 (0.73–2.78) 0.2994
No house member with clinical episode comparison
House member with clinical episode 3.43 (1.52–7.72) 0.0004
Low neighborhood non-adherence to MDA comparison
Mid neighborhood non-adherence to MDA 2.00 (0.87–4.60) 0.0879
High neighborhood non-adherence to MDA 2.85 (1.28–6.37) 0.0098
Mean village HBR 1.09 (1.05–1.13) <0.0001
Study month 1.19 (1.10–1.27) <0.0001
DOI: https://doi.org/10.7554/eLife.41023.008
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Discussion
The primary objective of this research was to look for a potential herd effect and at the impact of
non-adherence with regard to MDA for P. falciparum malaria. There was an apparent group level
effect from MDA adherence, suggesting herd protection and evident from three lines of evidence.
First, clinical episodes decreased among all groups for a longer period than the prophylactic
effect (approximately 1 month) of the administered antimalarials. This group level protective effect
from MDA was also evident in the rainy season following MDA (Figure 3) which corresponded to a
surge in vector activity (Appendix 1—figure 3). Once the P. falciparum outbreak began (M12), there
was a lag of approximately 1 month between the onset of clinical episodes in neighborhoods with
mid and low MDA adherence and then occurred in neighborhoods with high MDA adherence
(Figure 4A).
Second, neighborhoods with high MDA adherence never experienced the same levels of infection
as those with mid or low MDA adherence (Figure 4A). Individuals who participated in MDA but lived
in a neighborhood with low adherence had the highest risk of having a clinical episode whereas
those who did not participate in MDA but lived in a neighborhood with high adherence had the low-
est risk of having a clinical P. falciparum episode (Figure 4B). As has been described in other set-
tings, this individual-level finding may be related to relative perceptions of risk; with potential
complacency among individuals living in areas with lower levels of malaria (Koenker et al., 2013).
Third, the results from the multivariable logistic regression also suggest that living in a neighbor-
hood with a high proportion of people who did not adhere to MDA was a significant risk factor for
acquiring a clinical P. falciparum episode, after adjusting for individual MDA adherence and other
important predictors of having a clinical episode (Table 1). To our knowledge, this is the first docu-
mentation of a herd effect conferred by MDA for P. falciparum malaria.
The increase in clinical P. falciparum episodes post-MDA also corresponded to an increase in vil-
lage HBR. HBR also peaked in one other village (HKT) at the same time as in village TOT (Appen-
dix 1—figure 3), but occurred in the absence of a detectable parasite reservoir and the HBR did not
persist at high levels. Evidence also suggests that the MP in TOT was not functioning well in the first
year of the study (reported in Landier et al., 2017a). The combination of a persisting parasite reser-
voir and persistently high HBR (from M13 – M18) in TOT likely explains the drastically different
results between the study villages with regard to P. falciparum malaria elimination (Figure 2). A bet-
ter functioning MP in TOT would likely have reduced the size of the outbreak.
Clustering of uPCR-detected P. falciparum infections across houses occurred for limited periods
of time only prior to MDA (Figure 2). This clustering suggests that interventions such as reactive
case detection would have resulted in the detection of extra cases (of both clinical and uPCR-
detected P. falciparum) when searching within houses and occasionally in neighboring houses, but
these would have only been a small proportion of all infections within the villages (Parker et al.,
2016) and would not have halted transmission. Conversely, community based early diagnosis and
Table 2. Table of predictor variables (covariates) used in regressions.
Covariate Level Description
Age group Individual Ordinal; age groups: 0 to 4; 5 to 14; and 15 and above
Gender Individual Binary; male or female
Individual adherence to MDA Individual Binary; whether an individual participated in MDA or not (at least
one full round)
Household member with
clinical episode
Household Binary; one if another house member had a clinical episode and 0
if not
Household member with
uPCR-detected infection
Household Binary; one if another house member had a uPCR-detected
infection and 0 if not
Neighborhood MDA non-
adherence
Household/
neighborhood
Ordinal (split into tertiles); proportion of people within 100 m
radius who did not complete all three rounds of MDA
Human biting rate (HBR) Village Continuous; average number of bites per person per night
Study month Village Continuous; 1–26 (from May 2013 through June 2015); included as
a control
DOI: https://doi.org/10.7554/eLife.41023.007
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treatment and MDA with high participation, targeted at the village scale or larger, appear effective
at reducing prevalence, incidence, and transmission of P. falciparum (Landier et al., 2018b).
There are several limitations to this work. Individuals who did not participate in MDA also did not
participate in blood screenings immediately after MDA (i.e. M3 in village TOT). uPCR-detected infec-
tions are therefore likely to be underdiagnosed for these individuals, and it is likely that such infec-
tions clustered and overlapped with the clusters of non-adherence to MDA. While no genetic
analyses were done with samples from the village, it is likely that these underdiagnosed infections,
combined with the high HBR, led to a resurgence of clinical episodes. There is also evidence of a
poorly functioning MP in this village, which could have led to undiagnosed clinical episodes, espe-
cially during the beginning of the study. Some infections are likely to be acquired outside of the vil-
lage, leading to complex spatial patterns in infections that are mapped at the house level. Within-
household clustering can be the result of within-household transmission, or shared exposure outside
of the household or village among household members. Finally, these data come from a limited
number of villages (total of 4), with analysis of P. falciparum episodes coming from the sole village
that continued to have P. falciparum after MDA. Given that clinical P. falciparum episodes post-MDA
were only possible to analyze in a single village, and that neighborhoods were not discrete and over-
lapped (100 m buffer around each house), a neighborhood-level effect was not included in this analy-
sis. It is possible that the confidence intervals around the neighborhood MDA adherence variable
are therefore too small and would not have been statistically significant had a neighborhood effect
been included. This work would benefit from analyses with larger datasets.
This work has relevance with regard to further research and practice concerning MDA. While par-
ticipation is obviously crucial to success, there is unlikely to be a single adherence proportion that
can be applied in all situations. In this study, the elimination efforts were successful in three out of
four villages even though one of those villages (HKT) had a similar overall adherence to the village
with P. falciparum remaining after MDA (TOT). Likewise, this work points toward the need for con-
sidering spatial scale in MDA and in MDA adherence. Most current MDA trials and programs in the
GMS and elsewhere consider a single village or community as the target unit. In some cases, espe-
cially when high prevalence villages are spatially clustered across a landscape, it may be necessary to
target units above the village level (i.e. groups of villages).
Materials and methods
Study location and design
The study site consisted of four villages (KNH, TPN, HKT, and TOT) along the Myanmar-Thailand
border, in Kayin (Karen) State, Myanmar (Landier et al., 2017b). The villages were selected based
on P. falciparum malaria prevalence surveys using ultrasensitive quantitative PCR (uPCR)
(Imwong et al., 2015) and were part of a MDA pilot study (Landier et al., 2017b). The north-
ernmost village is approximately 105 km from the southernmost and the two closest villages, KNH
and TPN are within 10 km of each other (Figure 1). The study was conducted from May 2013
through June 2015.
A full population census was completed in each of the four study villages at baseline May – June
2013. Everyone enumerated in the census was given a unique identification code. Geographic coor-
dinates were collected for all houses in the four study villages and a unique identification code was
assigned to each house. All individuals were then linked to their respective houses.
Blood surveys were conducted at baseline in each village, aiming to screen all individuals above
an age of 9 months. Venous blood (3 mL) was drawn from each participant, transported to a central
laboratory and analyzed using a highly sensitive quantitative PCR (uPCR) assay with a limit of detec-
tion of 22 parasites per mL. (Imwong et al., 2014). Infections detected through these blood screen-
ings are hereafter referred to as uPCR-detected infections. Most (86%) uPCR-detected infections
were subclinical (Landier et al., 2017a) and clinical infections were provided the standard treatment
(see below).
A community-based malaria clinic (referred to as a malaria post or MP) was established in each vil-
lage at the beginning of the project, as part of the malaria intervention. Village health workers were
trained to diagnose malaria using rapid diagnostic tests (RDTs) and to treat RDT positive infections
with dose based on weight and age. The ID code of each participant who self-presented at the MP
Parker et al. eLife 2019;8:e41023. DOI: https://doi.org/10.7554/eLife.41023 9 of 22
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was recorded, along with RDT results, and these cases are hereafter referred to as clinical malaria
episodes of either P. falciparum or P. vivax. Malaria episodes were treated with dihydroartemisinin-
piperaquine (DHA + P) for P. falciparum and chloroquine for P. vivax. Radical cure for P. vivax was
not provided because the absence of G6PD (Glucose-6-phosphate dehydrogenase) tests required to
prevent hemolysis in G6PD individuals (Bancone et al., 2014; Chu et al., 2017).
MDAs were conducted in two villages at the beginning of the study (month 0, M0) and extended
to the two control villages beginning in month 9 (M9). Restricted randomization was used to decide
which villages received early or deferred MDA. MDA consisted of 3 days of DHA + P, with a single
low dose of primaquine on the third day, repeated over three months (M0, M1, M2 for the first
group and M9, M10, M11 for the control group). Follow-up blood surveys were conducted in each
village every third month after M0 until M18. A final full blood survey was completed in each village
at M24.
Mosquitoes were collected monthly using human landing catches to estimate the human biting
rate (HBR). Mosquito catching teams were based at five sites (both indoors and outdoors) within
each of the four study villages (total of 20 catch sites) for five consecutive nights during the study
period M0 through M20. Mosquitoes were caught using glass tubes and later identified morphologi-
cally (Ya-Umphan et al., 2017).
The locations of study villages, MPs, catch sites, and village houses are indicated in Figure 1.
Analysis
Variables
All individuals recorded in the census with a house address in the four study villages were included
in this analysis.
The data were aggregated into 1 month time steps and individuals were coded with a ‘1’ for any
month in which they presented at the village MP and were diagnosed with P. falciparum. Likewise,
individuals who did not have a clinical episode within a given month were coded with a ‘0’ for that
respective month. Individuals who were ever diagnosed with a clinical episode or uPCR-detected P.
falciparum infections were likewise coded as a ‘1’ for analyses of having ever been detected by
uPCR for an infection or having ever had a clinical episode during the study period.
Predictor variables (covariates) are listed in Table 2. Individual-level predictors included age
group, gender, infection status, and adherence to MDA. Household-level predictor variables
included a binary variable for whether or not another household member had a clinical episode and
whether or not another household member had a uPCR-detected infection.
Neighborhood MDA non-adherence was calculated as the proportion of people who took no
rounds of MDA within 100 m radius of each house in the study population. This proportion was cal-
culated for each house in the study villages and non-adherence proportions were then attributed to
individuals based on the house to which they were attributed.
The human biting rate (HBR) for primary vectors (Anopheles minimus s.l., An. maculatus s.l., and
An. dirus s.l.) was calculated for each month.
Exploratory spatial and temporal analyses
All predictor variables were explored in bivariate analyses. Unadjusted odds ratios (UOR) were calcu-
lated for binary predictors and Wilcox rank sum tests were calculated for continuous variables.
Cumulative hazards curves were used to analyze temporal patterns in clinical episodes. uPCR-
detected infections (from surveys) and clinical episodes (from the MPs) were mapped at the house
level across time. Maps were created for each village and each survey time point (months 0 through
24: M0 – M24), with clinical episodes aggregated to align with surveys (i.e. M1, M2 and M3 aggre-
gated into M3).
The weighted standard distance deviation (SDD) was used to visually analyze the distribution of
clinical P. falciparum episodes for each survey time point in the one village with sufficient P. falcipa-
rum episodes (TOT) post-MDA. Clinical episodes were aggregated to align with survey time points
(i.e. months 1 through 3 were aggregated and plotted in month 3). One SDD was calculated, corre-
sponding to approximately 68% of all points falling inside of the resulting circle.
Scan statistics were used to test for clustering of uPCR-detected P. falciparum infections across
survey months; clinical P. falciparum episodes across all months of the study period; and MDA non-
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participation (Kulldorff, 1997). The scan statistics used a moving window (a circle) that centered on
each point in the village, testing for the relative risk of cases given a population size within the circle
in comparison to the risk outside of the circle (Kulldorff, 1997). The circle increased in size until it
included half of the population and then moved to the next geographic reference point. For Plasmo-
dium infections and malaria episodes the space-time discrete Poisson model was used, whereas for
MDA participation a purely spatial Poisson model was used (Kulldorff, 1997) (as MDAs were com-
pleted within a 3-month time period).
Multivariable logistic regression
A multivariable mixed effects logistic regression was used to estimate model adjusted odds ratios
(AOR) and confidence intervals for predictor covariates with regard to the individual odds of having
a clinical P. falciparum malaria episode. Since clinical P. falciparum episodes were almost exclusively
limited to a single village post-MDA (village TOT), the analysis of clinical P. falciparum episodes
focuses on this village alone.
Covariates for these models are listed in Table 2 and included individual, household, neighbor-
hood, and village-level predictors. Model and variable selection are described in detail in Appendix
1. Results for uPCR-detected P. falciparum infections are listed in Appendix 1. While this study
focuses on P. falciparum, P. vivax data were also collected and are included in secondary analyses in
the Appendix.
Software
Exploratory statistics and regressions were calculated using R (version 3.4.3; https://cran.r-project.
org/) and the ‘epiR’, ‘lme4’, and ‘survival’ packages. All maps were created using ArcGIS 10.5
(https://www.arcgis.com/). Exploratory spatial data analysis was conducted using ArcGIS 10.5 and
SatScan v9.5 (https://www.satscan.org/). The neighborhood participation variable was created using
ArcGIS and the Python programming language (version 3.5.2; https://www.python.org/).
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Model selection and variable specification
Regressions for clinical episodes
A multivariable mixed effects logistic regression was used to estimate model adjusted odds
ratios (AOR) and confidence intervals for predictor covariates with regard to the individual
odds of having a clinical P. falciparum malaria (P. vivax results provided below). Covariates for
this model are listed in Table 2 and included individual, household, neighbourhood, and
village-level predictors.
Clinical P. falciparum episodes were almost exclusively limited to a single village post-MDA
(village TOT), and the regression analyses of clinical P. falciparum episodes and uPCR-
detected infections focuses on this village alone (whereas analyses for P. vivax included all four
villages). The models for clinical episodes included a random intercept to account for repeated
measures within individuals across the study period. During model selection, a random
intercept was also tested for household but resulted in no significant model improvement and
was therefore excluded in subsequent models.
Different specifications (continuous, binary, ordinal) for individual and neighborhood level
MDA adherence were tested in initial models. The continuous specification for individual level
MDA adherence was calculated as the proportion of all doses of dihydroartemisinin-
piperaquine taken (total of 9 possible). A binary specification for whether or not an individual
had taken one or more rounds of MDA was also tested. The continuous specification for
neighborhood level MDA non-adherence was the proportion of all individuals within a 100 m
radius who took no rounds of MDA. An ordinal specification was also tested, based off of the
distribution of the data and categorized by tertiles (Appendix 1—table 1). The use of
categorical or binary variables allowed us to test for temporal effects by different levels of
neighborhood participation and by whether or not an individual participated in MDA via
hazards curves for each category (Figure 4) These categorical specifications were chosen for
the final models in the manuscript based on model fit statistics (AIC and BIC did not indicate
that models with continuous predictors provided a better fit) and in order to maintain
consistency with the visualizations in Figure 4. The model with continuous specifications for
neighborhood MDA non-adherence and individual adherence to MDA is provided here for
clinical P. falciparum episodes (Appendix 1—table 2).
Appendix 1—table 1. Terciles (lower, middle and upper 1/3) of MDA non-adherence (% taking
no rounds of MDA) in TOT
High non-adherence >0.294
Mid non-adherence >0.20 and <0.294
Low non-adherence <0.20
DOI: https://doi.org/10.7554/eLife.41023.011
Appendix 1—table 2. Multivariable mixed effects logistic regression for odds of having a
clinical P. falciparum episode. The model includes a random intercept for individual
participants, with repeat observations occurring within individuals over the study period. Unlike
the model in the main text (Table 1) neighborhood non-adherence to MDA and individual
adherence to MDA are continuous covariates. Study month was included as a control (a linear
specification was used, but polynomial specifications were also tested). The covariates for
human biting rate (HBR) and having a house member with a clinical episode in the same month
were specified as time-varying covariates.
Covariate AOR p-value
Appendix 1—table 2 continued on next page
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Appendix 1—table 2 continued
Covariate AOR p-value
Age 0 to 4 comparison
Age 5 to 14 3.5 (1.3–9.0) 0.0112
Age 15 plus 2.2 (0.9–5.6) 0.1014
female comparison
Male 1.2 (0.7–2.2) 0.5147
no house member with clinical episode comparison
house member with clinical episode 3.8 (1.8–7.7) 0.0003
proportion of MDA doses complete 1.0 (1.0–1.1) 0.4488
proportion of non-adherers in neighborhood 1.4 (1.0–1.8) 0.0380
mean village HBR 1.1 (1.1–1.1) <0.0001
study month 1.2 (1.1–1.3) <0.0001
DOI: https://doi.org/10.7554/eLife.41023.012
The sensitivity of the model results with regard to the neighborhood MDA non-adherence
buffer size was also tested. Neighborhood MDA-non-adherence was tested with varying
buffer sizes, beginning with a radius of 20 m and going up to a radius of 220 m, by 40 m
intervals. Neighborhood buffers from 60 m to 140 m were statistically significant and had
comparable model adjusted odds ratios (at 60 m: AOR = 2.33; CI: 1.03–5.25; at 100 m:
AOR = 2.84; CI: 1.29–6.27; at 140 m: AOR = 2.35; CI: 1.06–5.19). Small buffers (i.e. 20 m)
included only one or very few households. At larger buffer sizes (>180 m) most houses were
included within a buffer (furthest distance between any two houses was approximately 1 km)
leading to little spatial heterogeneity in participation across the village.
Regressions for uPCR-detected infections
Multivariable logistic regressions were used to test for associations between predictor
variables and the individual odds of being diagnosed by uPCR with a P. falciparum or P.
vivax infection after MDA. Some individuals were detected with infections during multiple
repeated screenings. However we are unable to differentiate between new and old
infections with these data. We therefore tested for associations between potential risk
factors and the log odds of having ever been detected by uPCR with an infection after MDA.
Individuals who were ever diagnosed as infected with P. falciparum by uPCR were coded
with a ‘1’ and individuals who were never diagnosed with an infection were coded as a ‘0’.
Since these models were not longitudinal and only have a single observation per individual,
time-varying covariates (such as HBR) were not included. Predictor covariates in these
models are listed and described in Table 2. Results for uPCR-detected P. falciparum are
presented in Appendix 1—table 3 and results for uPCR-detected P. vivax are presented in
Appendix 1—table 5.
Appendix 1—table 3. Logistic regression for the odds of having a uPCR-detected P.
falciparum infection after MDA. Individuals in the data were coded as having an infection if
they were ever determined by uPCR to have an infection through blood screenings in full
village blood surveys after MDA. Almost all P. falciparum episodes occurred in a single village
(TOT) and the analysis for P. falciparum was only conducted on data from that village. HBR is
not included in this regression as it varies across time.
Covariate AOR p-value
0 to 4 comparison
five to 14 6.1 (1.1–113.9) 0.0877
Appendix 1—table 3 continued on next page
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Appendix 1—table 3 continued
Covariate AOR p-value
15 plus 5.5 (1.1–99.3) 0.1017
female comparison
male 1.3 (0.6–2.7) 0.5217
participated in no rounds of MDA comparison
participated in MDA (at least one round) 0.4 (0.2–1.1) 0.0955
no house member with uPCR infection comparison
house member with uPCR infection 1.1 (0.4–2.7) 0.8039
no house member with clinical episode comparison
house member with clinical episode 1.7 (0.7–3.8) 0.2029
low neighborhood non-adherence to MDA comparison
mid neighborhood non-adherence to MDA 1.1 (0.4–3.2) 0.8743
high neighborhood non-adherence to MDA 2.6 (1.0–7.1) 0.0488
number of surveys attended 1.3 (1.1–1.6) 0.0075
DOI: https://doi.org/10.7554/eLife.41023.013
Weighted Standard Distance Deviation (SDD)
The SDD gives an indication of how points deviate from the mean center. Weighted SDD are
calculated by finding the geometric mean center of all points in a given time frame,
weighted by the number of clinical episodes (Chu et al., 2017; Ya-Umphan et al., 2017).
The SDD is frequently represented by a circular map layer centered on the weighted mean
with the standard distance as the radius. The formula for the weighted SDD is:
SDD¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPn
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where wi is the weight at point i;
xi and yi are geographic references for point i;
{XMC, YMC} is the geometric mean center (MC) for the features.
Results from the analysis of clinical Plasmodium vivax episodes
and uPCR-detected P. vivax infections
Of 3229 villagers included in the study, 216 participants were diagnosed with clinical P. vivax.
611 were found to have P. vivax infections by uPCR. P. vivax infections were more prevalent
in males than in females (UOR: 1.7; CI: 1.4–2.0). P. vivax infections were reduced significantly
following MDA in all villages but returned in subsequent months in most villages (as
expected given that radical cure was not provided), with the exception of village TPN.
P. vivax infections were widespread throughout the study villages at baseline but no
spatial clustering pattern was detected at month 0 (M0) (Appendix 1—figure 1). Village HKT
had a cluster at M3; village KNH had one persistent cluster from M9 through M18; and
village TOT had two clusters at M24 (Appendix 1—figure 1). Clusters of clinical P. vivax
episodes also lingered in village KNH (M3 through M14 (17 episodes) and then M12 through
M24 (six episodes)) and in village TOT (M12 through M21 (31 episodes) and M19 through
M23 (18 episodes)). There was a cluster of clinical P. vivax episodes in village HKT during
M23 and M24 (including 23 episodes).
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Appendix 1—figure 1. Clinical P.vivax episodes (yellow square points) and uPCR-detected P.
vivax infections (blue dots) at house level over time for each of the four study villages.
Statistically significant clusters (detected using SaTScan) are indicated for both clinical
episodes (underlying yellow circles) and PCR-detected infections (underlying blue circles).
MDA completion is indicated by the dark brown box bordering the survey time period
(months 0 through 24, indicated as M0 – M24 along the x-axis). Blood stage P. vivax
parasites were largely cleared following MDA. Since no accurate field diagnostic for glucose-
6-phosphate dehydrogenase (G6PD) deficiency existed at the time, it was deemed unsafe to
provide 7 or 14 days of the hypnozoitocidal drug primaquine. Many of the subsequent
infections and clinical episodes are likely a result of re-emergence of hypnozoite-stage
parasites rather than new P. vivax infections.
DOI: https://doi.org/10.7554/eLife.41023.014
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Appendix 1— figure 2. Spatial clusters (detecting using SatScan) of non-participation in MDA.
DOI: https://doi.org/10.7554/eLife.41023.015
Appendix 1— figure 3. Human biting rate (HBR) for primary vectors by study month.
DOI: https://doi.org/10.7554/eLife.41023.016
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Appendix 1— figure 4. Unspeciated uPCR-detected infection for each village and survey.
DOI: https://doi.org/10.7554/eLife.41023.017
Longitudinal analysis of clinical P. vivax episodes
Clinical P. vivax episodes exhibited household clustering. Individuals who lived in a house
with someone who had a clinical P. vivax episode during the same month had nearly six
times the odds of having a clinical P. vivax episode when compared to those who did not live
in a house with someone who had a clinical P. vivax episode (AOR: 5.8; CI: 3.4–9.9)
(Appendix 1—table 4). Clinical P. vivax episodes were also most common among the
youngest age group (0 to 4 year olds), with those who were age 15 and above having a 60%
decrease in the odds of having a clinical episode when compared to the 0 to 4 age group
(AOR: 0.4; CI: 0.2–0.9).
Appendix 1—table 4. Multivariable mixed effects logistic regression for odds of having a
clinical P. vivax episode. The model includes a random intercept for individual participants,
with repeat observations occurring within individuals over the study period. Study month was
included as a control (a linear specification was used, but polynomial specifications were also
tested). The covariates for human biting rate (HBR) and having a house member with a clinical
episode in the same month were specified as time-varying covariates.
Covariate AOR p-value
Age 0 to 4 comparison
Age 5 to 14 1.0 (0.4–2.4) 0.9945
Age 15 plus 0.4 (0.2–0.9) 0.0358
female comparison
male 0.8 (0.4–1.5) 0.4687
participated in no rounds of MDA comparison
participated in MDA (at least one round) 1.7 (0.7–4.3) 0.2678
no house member with clinical episode comparison
house member with clinical episode 5.8 (3.4–9.9) <0.0001
low neighborhood non-adherence to MDA comparison
mid neighborhood non-adherence to MDA 1.6 (0.3–7.6) 0.5546
high neighborhood non-adherence to MDA 1.8 (0.3–9.8) 0.5205
mean village HBR 1.0 (1.0–1.1) 0.1447
village KNH comparison
Appendix 1—table 4 continued on next page
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Appendix 1—table 4 continued
Covariate AOR p-value
village TPN 0.6 (0.2–1.8) 0.3666
village HKT 0.3 (0.1–1.5) 0.1329
village TOT 0.6 (0.1–3.4) 0.6074
study month 1.0 (1.0–1.1) 0.0126
DOI: https://doi.org/10.7554/eLife.41023.018
Logistic regression for odds of having a uPCR-diagnosed infection after MDA uPCR
detected P. vivax infections occurred mostly in older children (AOR: 2.6; CI: 1.7–3.9), adults
(AOR: 2.1; CI: 1.4–3.2) and males (AOR: 1.8; CI: 1.4–2.2) (Appendix 1—table 5). Individuals
who lived in a house with someone else with a uPCR-detected P. vivax infection had 1.5
times the odds (CI: 1.2–1.9) of also having a uPCR detected infection after MDA
(Appendix 1—table 5).
Appendix 1—table 5. Multivariable logistic regression for the odds of having a uPCR
detected P. vivax infection after MDA. Individuals in the data were coded as having an
infection of either species if they were ever determined by uPCR to have an infection through
blood screenings in full village blood surveys after MDA.
Covariate AOR p-value
0 to 4 comparison
five to 14 2.6 (1.7–3.9) <0.0001
15 plus 2.1 (1.4–3.2) 0.0002
female comparison
male 1.8 (1.4–2.2) <0.0001
participated in no rounds of MDA comparison
participated in MDA (at least one round) 0.6 (0.4–0.8) 0.0027
no house member with uPCR infection comparison
house member with uPCR infection 1.5 (1.2–1.9) 0.0022
no house member with clinical episode comparison
house member with clinical episode 1.3 (1.0–1.7) 0.0284
low neighborhood non-adherence to MDA comparison
mid neighborhood non-adherence to MDA 0.6 (0.4–1.1) 0.0994
high neighborhood non-adherence to MDA 0.6 (0.4–1.1) 0.0945
KNH comparison
TPN 1.0 (0.7–1.5) 0.8617
HKT 1.4 (0.8–2.5) 0.2614
TOT 5.4 (2.9–9.8) <0.0001
number of surveys attended 1.4 (1.3–1.5) <0.0001
DOI: https://doi.org/10.7554/eLife.41023.019
Discussion
Post-MDA clinical P. vivax episodes exhibited spatiotemporal clustering within houses. uPCR-
detected P. vivax infections also clustered within houses. While there was an immediate
reduction in blood-stage P. vivax following MDA (evident in Appendix 1—figure 1) there
was no overall effect of MDA on the risk of subsequent clinical episodes or uPCR-detected
infections over the entire surveillance period.
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Appendix 1—table 6. Household and population counts for study villages Data used in this
analysis are available following the Mahidol-Oxford Tropical Medicine Research Unit data
access policy. Both the policy and application form are available at: http://www.tropmedres.ac/
data-sharing.
Village Households Population
KNH 86 504
TPN 75 468
HKT 176 1338
TOT 149 919
total 486 3229
DOI: https://doi.org/10.7554/eLife.41023.020
Clinical P. vivax episodes occurred more commonly among the youngest age group (0 to
4) while uPCR-detected infections occurred more commonly among adults. This pattern was
previously described in Thai-Burma (now referred to as Myanmar) border populations over
two decades ago (Kulldorff, 1997) and is likely the result of some level of acquired immunity
to P. vivax infections with time. Both adults and children are exposed to similar levels of P.
vivax transmission, yet in children the infection is more likely to result in clinical symptoms
whereas in adults, many of the infections are likely to become or remain asymptomatic.
Clustering of P. vivax across houses persisted across time before and after MDA
(Appendix 1—figure 1). Overlapping clusters of clinical P. vivax episodes and uPCR-
diagnosed P. vivax infections were observed in KNH (M9 through M15) and TOT (M24).
There were overlapping clusters of clinical P. vivax episodes and clinical P. falciparum
episodes in village KNH (M5 – M7) and village TOT (M12 – M18).
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